ライフサイエンスコーパス: embryonal

1 owed a 1.5-cm mixed germ cell tumor with 85% embryonal, 10% yolk sac tumor, and 5% mature teratoma hi

2 ers reported that recessive mutations in the embryonal acetylcholine receptor g subunit (CHRNG) can c

3 ified germline-inactivating mutations in the embryonal acetylcholine receptor gamma subunit (CHRNG) i

4 n of clinical cases revealed that human RMS (embryonal, alveolar, and pleomorphic) harbored human cyt

5 In this Review, we specifically focus on embryonal and alveolar rhabdomyosarcoma, synovial sarcom

6 was absent in almost all human RMS, both for embryonal and alveolar RMS subtypes.

7 es from each major rhabdomyosarcoma subtype (embryonal and alveolar).

8 yosarcoma has two major histologic subtypes, embryonal and alveolar, each with distinct clinical, mol

9 Y-DOTATOC; diagnoses included neuroblastoma, embryonal and astrocytic brain tumors, paraganglioma, mu

10 -catenin transcriptional target and multiple embryonal and neural crest malignancies have oncogenic a

11 though well-developed mouse models exist for embryonal and pleomorphic rhabdomyosarcomas, neither a s

12 ferentiated fetal cells, less differentiated embryonal and undifferentiated small cells (SCU) progres

13 Because of small numbers of embryonal arterial cells undergoing EHT and the paucity

14 l groups were elevated in both cotyledon and embryonal axis.

15 e of the resemblance of the spheroids to the embryonal blastocyst and their resistance to traditional

16 nerated spheroids in vitro that resemble the embryonal blastocyst.

17 ne profile resemblance of these spheroids to embryonal blastocysts, we wondered whether they might ex

18 d, constitutively active Notch1 or Notch2 in embryonal brain tumor cell lines caused antagonistic eff

19 In a pediatric embryonal brain tumor tissue microarray, we observed an

20 of medulloblastoma, a histologically similar embryonal brain tumor.

21 with deregulated E2F1 show the formation of embryonal brain tumors such as medulloblastoma, choroid

22 Pediatric embryonal brain tumors with multilayered rosettes demons

23 of Notch2, we analyzed its gene dosage in 40 embryonal brain tumors, detecting an increased copy numb

24 in both nonneoplastic neural stem cells and embryonal brain tumors, such as medulloblastoma, which a

25 nd academic declines in children treated for embryonal brain tumors.

26 quantitative PCR to measure hTERT mRNA in 50 embryonal brain tumors.

27 atric patients previously operated on for an embryonal brain tumour (13 patients prospectively diagno

28 alamocortical tract involvement in childhood embryonal brain tumour patients who developed posterior

29 d rosettes (ETMRs) are aggressive paediatric embryonal brain tumours with a universally poor prognosi

30 Neuroblastoma, an embryonal cancer of neural crest origin, shows metastase

31 Neuroblastoma (NBL) is an embryonal cancer of the sympathetic nervous system (SNS)

32 tivity directs initiation and progression of embryonal cancer.

33 yndrome associated with an increased risk of embryonal cancers in childhood.

34 ann syndrome (BWS), which increases risk for embryonal cancers, including Wilms tumor.

35 (NSE), the latter including the pluripotent embryonal carcinoma (EC) and its differentiated derivati

36 Pluripotent cells within embryonal carcinoma (EC) can differentiate in vivo or in

37 used the well-characterized pluripotent P19 embryonal carcinoma (EC) cell culture model of neuro-ect

38 Using human embryonal carcinoma (EC) cells as bait, approximately 3

39 Embryonal carcinoma (EC) cells have served as a model to

40 et of neuroectodermal differentiation in P19 embryonal carcinoma (EC) cells three independent techniq

41 OCT4 levels and increases the resistance of embryonal carcinoma (EC) cells to cisplatin and bleomyci

42 therapy, and testicular cancer-derived human embryonal carcinoma (EC) cells undergo a p53-dominant tr

43 silenced genes in cancer cells; however, in embryonal carcinoma (EC) cells, CBX7 can initiate stable

44 bryonic stem (ES) cells and can give rise to embryonal carcinoma (EC) cells, the stem cells of testic

45 erentiated cells, but not in the parental F9 embryonal carcinoma (EC) cells.

46 wn that p53 repression in TGCT-derived human embryonal carcinoma (EC) is relieved upon treatment with

47 de of Noxa reduced the apoptotic response of embryonal carcinoma (EC) NTERA2 cells to cisplatin.

48 us GCTs (NSGCTs) can be further divided into embryonal carcinoma (EC), teratoma (T), yolk sac tumor (

49 ity and trophoblast differentiation of mouse embryonal carcinoma and embryonic stem cells.

50 Presence of vascular invasion together with embryonal carcinoma and rete testis invasion in the test

51 We further identified the embryonal carcinoma antigen podocalyxin-like protein 1 (

52 In the embryonal carcinoma cell line NT2/D1, ectopic DeltaN-p63

53 ct4 gene locus in retinoic acid (RA)-treated embryonal carcinoma cell line P19, which involves recept

54 Incubation of a human embryonal carcinoma cell line with NMM reduces its stem

55 clude two regions of promoter activity in an embryonal carcinoma cell line, Tera2EC.

56 ell lines, five normal human tissues, and an embryonal carcinoma cell line.

57 significantly greater levels in human ES and embryonal carcinoma cell lines than in control samples.

58 HSTMs shared a common precursor, arguably an embryonal carcinoma cell resulting from a reprogrammed p

59 the Hoxa1, RARbeta2, and Cyp26A1 RAREs in F9 embryonal carcinoma cells (teratocarcinoma stem cells) d

60 lated during neuronal differentiation in P19 embryonal carcinoma cells and epigenetic changes play an

61 ted knockdown of USP2a in NTERA-2 testicular embryonal carcinoma cells and MCF7 breast cancer cells c

62 rget of GATA-6 regulation in differentiating embryonal carcinoma cells and that, in vivo, the express

63 These studies employed F9 embryonal carcinoma cells and their differentiated cells

64 protein synthesis-independent manner in P19 embryonal carcinoma cells by inactivation of NF-kappa B.

65 wn of Cripto-1 expression in human and mouse embryonal carcinoma cells desensitized the ligand-induce

66 FoxA proteins are induced when F9 embryonal carcinoma cells differentiate into visceral en

67 rmation of primitive endoderm from mouse P19 embryonal carcinoma cells in response to retinoic acid,

68 neural cells derived from embryonic stem and embryonal carcinoma cells in vitro and neural stem cells

69 st cancer cells and suppressed the growth of embryonal carcinoma cells in vitro.

70 Studies of miR-125b function in mouse P19 embryonal carcinoma cells induced to develop into neuron

71 of the expressing differentiated cells with embryonal carcinoma cells or by treatment of the differe

72 Removal of endogenous OAZ from pluripotent embryonal carcinoma cells prevents the induction of Smad

73 Here, we report that human embryonal carcinoma cells proliferate and produce differ

74 that overexpressing Hoxa2 in cultures of P19 embryonal carcinoma cells reduced the frequency of spont

75 ion of p53 and p53 pathway genes and renders embryonal carcinoma cells relatively resistant to cispla

76 Embryonal carcinoma cells represent the pluripotent enti

77 rentiation, whereas studies with pluripotent embryonal carcinoma cells suggest that this pathway prom

78 ed large sets of genes in embryonic stem and embryonal carcinoma cells that are associated with the t

79 tutive levels of this BH3-only protein prime embryonal carcinoma cells to undergo rapid and massive a

80 o DNA methylation-associated inactivation in embryonal carcinoma cells were transfected into differen

81 sttranscriptionally in embryonic stem cells, embryonal carcinoma cells, and primary tumors.

82 cardiomyocyte differentiation in pluripotent embryonal carcinoma cells, and we show that this involve

83 d in mES cells and in Ntera-2 or NCCIT human embryonal carcinoma cells, as compared with cells growin

84 In P19 mouse embryonal carcinoma cells, expression of the MOR was gre

85 we show that in mouse embryoid bodies or F9 embryonal carcinoma cells, RARs occupy a large repertoir

86 We have studied the function of LINC in F9 embryonal carcinoma cells, which are distinguished by a

87 nd murine mammary stem/progenitor cells, and embryonal carcinoma cells.

88 ouse embryonic stem (mES) cells and in human embryonal carcinoma cells.

89 erum/cytokine-free expansion of leukemic and embryonal carcinoma cells.

90 ctodermal differentiation of pluripotent P19 embryonal carcinoma cells.

91 colocalizing with OCT4 in Ntera2 testicular embryonal carcinoma cells.

92 ons of dorsal root ganglion (DRG) and in P19 embryonal carcinoma cells.

93 platin in testicular germ cell-derived human embryonal carcinoma cells.

94 vity that accompanies the differentiation of embryonal carcinoma cells.

95 s the specificity of RNA interference in p19 embryonal carcinoma cells.

96 f RA-induced neuronal differentiation in p19 embryonal carcinoma cells.

97 fferentiation and cell cycle arrest in human embryonal carcinoma cells.

98 ng RA-driven differentiation of human NT2/D1 embryonal carcinoma cells.

99 ribosomal frameshifting signal of the mouse embryonal carcinoma differentiation regulated (Edr) gene

100 protein-coupled receptor is regulated during embryonal carcinoma differentiation.

101 ates 9 of 15 genes in this pathway in the F9 embryonal carcinoma model and 11 of 15 pathway genes in

102 of neural progenitor cells, using the mouse embryonal carcinoma P19 cell line as a model system.

103 Using mouse embryonal carcinoma P19 cells as a neural differentiatio

104 X protein levels are also increased in mouse embryonal carcinoma P19 cells during retinoic acid (RA)-

105 knockdown Smn gene expression in the murine embryonal carcinoma stem cell line P19, which can be dif

106 We used an embryonal carcinoma stem cell model and show here that (

107 Cs across species and between human ESCs and embryonal carcinoma stem cells suggest that while plurip

108 r the differentiation of cultured P19 murine embryonal carcinoma stem cells to beating cardiac myocyt

109 quired for the differentiation of murine P19 embryonal carcinoma stem cells to beating cardiac myocyt

110 ssessing the least (median 1, range 0-4) and embryonal carcinoma the most (median 8.5, range 6-12).

111 Embryonal carcinoma was the most frequent RPLND histolog

112 ed for 95 previously untreated patients with embryonal carcinoma with or without other germ cell comp

113 Comparison of embryonal carcinoma with seminomas revealed relative ove

114 -cm tumor that was 95% yolk sac tumor and 5% embryonal carcinoma, and retroperitoneal lymph node diss

115 erentiated human GCTs, such as seminomas and embryonal carcinoma, but not in normal testis or in diff

116 ion of several stem cell-associated genes in embryonal carcinoma, including several core "stemness" g

117 Required histology included yolk sac, embryonal carcinoma, or choriocarcinoma.

118 These results show that human embryonal carcinoma-derived progeny interact with mouse

119 ith good clinical prognosis in patients with embryonal carcinoma.

120 Pluripotent embryonal carcinomas (EC) are the malignant counterparts

121 Embryonal carcinomas (EC) comprise a subset of TGCTs tha

122 the pluripotent cells (embryonic stem cells, embryonal carcinomas and induced pluripotent cells).

123 that exhibited coordinated overexpression in embryonal carcinomas and seminomas, which included the k

124 lain the differences in pluripotency between embryonal carcinomas and seminomas.

125 and nonseminomas, which include pluripotent embryonal carcinomas as well as other histologic subtype

126 d malignant tumors, with yolk sac tumors and embryonal carcinomas positive for alpha-fetoprotein, cyt

127 t has implications for both undifferentiated embryonal cells and for cancers in which pocket protein

128 ctors and homeobox proteins predominating in embryonal cells and glycoproteins and immunoglobulin-rel

129 some Suz12 target genes are bound by OCT4 in embryonal cells and suggest that OCT4 maintains stem cel

130 otein kinase p38 in mouse F9 teratocarcinoma embryonal cells.

131 m impaired differentiation of neuronal crest embryonal cells.

132 Embryonal central nervous system (CNS) tumors, which com

133 ally led to the proposal that tumors take on embryonal characteristics, the so called embryonal theor

134 In the present study, we show that human embryonal CNS tumor cell lines and surgical tumor specim

135 ts younger than 3 years with newly diagnosed embryonal CNS tumors is 14 mg.

136 gnancy with multifunctional effects in human embryonal CNS tumors.

137 Doxycycline (Dox) was administered from embryonal day 14 to postnatal day 7, and lungs were stud

138 sL) overexpression, treated with Dox between embryonal day 15 and postnatal day 3, served as a model

139 tnatal day 7, and lungs were studied between embryonal day 19 and postnatal day 21.

140 n many important cellular processes, notably embryonal development and cellular differentiation.

141 en neighboring cells that are crucial during embryonal development and in adults.

142 f fundamental biological processes including embryonal development and tumorigenesis.

143 n tumors, may be associated with the special embryonal development morphologic transition of this mal

144 Basement membrane transmigration during embryonal development, tissue homeostasis and tumor inva

145 Embryonal (ERMS) and alveolar (ARMS) are the two major R

146 n occurs as two major histological subtypes, embryonal (ERMS) and alveolar (ARMS).

147 rhabdomyosarcoma include alveolar (ARMS) and embryonal (ERMS) tumors.

148 negative associations between later life and embryonal expression profiles.

149 Here, we examine the growth pattern of embryonal fibroblasts derived from Lsh-/- mice.

150 Surprisingly, mouse embryonal fibroblasts that are null for p19(ARF) or P53,

151 ant role in mitotic defects of Lsh-/- murine embryonal fibroblasts, possibly by altering chromatin st

152 reased risk of developing hepatoblastoma, an embryonal form of liver cancer, suggesting that Wnt affe

153 levels of tropoelastin mRNA were low during embryonal growth and increased substantially in neonates

154 (YS) diameter, crown-rump length (CRL), and embryonal heart rate (HR) dimensions to identify early p

155 eta-catenin and differentiation status, with embryonal hepatoblastomas expressing full-length beta-ca

156 natures of gliogenic progenitors involved in embryonal hindbrain development.

157 In rhabdomyosarcoma, genitourinary site and embryonal histology confer a relatively favorable progno

158 Patients with embryonal histology had a significantly better 5-year EF

159 Eight patients had embryonal histology, and 24 patients had alveolar histol

160 , age less than 10 years, low IRS group, and embryonal histology.

161 epitope tagging in stably transfected human embryonal kidney (HEK) 293 cells, immunoaffinity purific

162 Human embryonal kidney 293 alphaIIbbeta3 cells overexpressing

163 A) negatively regulate the adhesion of human embryonal kidney 293 cells expressing alpha(IIb)beta(3)

164 Ib)beta(3) in resting platelets and in human embryonal kidney 293 cells expressing alpha(IIb)beta(3).

165 PAR-/-murine embryonic fibroblasts and human embryonal kidney 293 cells, SuPAR functions as a partial

166 moter methylation arrays, we show that human embryonal kidney cells over-expressing WT1 acquire DNA m

167 uced DNMT3A in Wilms' tumour cells and human embryonal kidney-derived cell lines.

168 eptors in mouse embryos often leads to early embryonal lethality.

169 Childhood solid tumors often arise from embryonal-like cells, which are distinct from the epithe

170 Neuroblastoma is a neural crest-derived embryonal malignancy, which accounts for 13% of all pedi

171 The microtubule arrays appear normal in the embryonal mass cells, but the microtubule network is par

172 or cell types: the meristematic cells of the embryonal mass on one pole and the terminally differenti

173 es and F-actin changes successively from the embryonal mass towards the distal end of the embryo susp

174 Pa ESP was expressed in the proliferating embryonal mass, while it was absent in the suspensor cel

175 , Cripto-1 is enriched in a subpopulation of embryonal, melanoma, prostate, and pancreatic cancer cel

176 netic alterations associated with the unique embryonal morphology of nonseminomatous subtypes of test

177 formed rhabdomyosarcoma-like tumors with an embryonal morphology, capable of invasion and metastasis

178 This embryonal neoplasm often encases vascular structures and

179 volved in the progression of these malignant embryonal neoplasms.

180 asomotor nerve cells, which originate in the embryonal neural crest can lead to their formation.

181 Neuroblastoma arises from the embryonal neural crest secondary to a block in different

182 in low-stage neuroblastoma tumors and normal embryonal neuroblasts, but reduced in late-stage neurobl

183 quiescently HCMV-infected human pluripotent embryonal NTera2 cells (NT2) to model HCMV reactivation,

184 ase using the terms neoplasms, germ cell, or embryonal or testicular neoplasms restricted to humans,

185 ges: pediatric solid tumors are typically of embryonal origin, whereas adult tumors are usually carci

186 cholangiocarcinoma, which clustered by their embryonal origin.

187 growth of two different rhabdomyosarcoma (RD embryonal P = 0.00008; Rh30 alveolar P = 0.0002) cell li

188 During embryonal period, complete obliteration of the urachus a

189 e isoform cross-linking collagen IV in mouse embryonal PFHR-9 cells.

190 ant flow in the aorta and extending into the embryonal-placental circulation, which was evident after

191 ll transcriptome atlas of >65,000 cells from embryonal pons and forebrain, two major tumor locations.

192 These findings reveal embryonal precursors from which unilateral and multifoca

193 actor Hnf4alpha leads to derepression of the embryonal proto-oncogene Hmga2 in Nkx2-1-negative tumors

194 n of the invadopodia component Tks5long, the embryonal proto-oncogene Hmga2, and the epithelial-to-me

195 reviously by Oomizu et al to be expressed in embryonal rat epidermis at the mRNA level.

196 One million alveolar (Rh30) and embryonal (RD) rhabdomyosarcoma cells with stably transf

197 ll carcinoma (BCC), medulloblastoma (MB) and embryonal rhabdhomyosarcoma (eRMS), three principle tumo

198 Embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyo

199 Wnt signaling is downregulated in embryonal rhabdomyosarcoma (ERMS) and contributes to the

200 Embryonal Rhabdomyosarcoma (ERMS) and Undifferentiated P

201 y resected, or gross residual (orbital only) embryonal rhabdomyosarcoma (ERMS) had 5-year failure-fre

202 Embryonal rhabdomyosarcoma (ERMS) is a childhood cancer

203 Embryonal rhabdomyosarcoma (ERMS) is a common pediatric

204 Embryonal rhabdomyosarcoma (ERMS) is a devastating cance

205 Embryonal rhabdomyosarcoma (ERMS) is an aggressive pedia

206 fusion protein PAX3-FOXO1 or PAX7-FOXO1, and embryonal rhabdomyosarcoma (ERMS), which is genetically

207 port that YAP1 activity is elevated in human embryonal rhabdomyosarcoma (ERMS).

208 n (VA) for patients with subset-one low-risk embryonal rhabdomyosarcoma (ERMS; stage 1/2 group I/II E

209 he spontaneous development of muscle-derived embryonal rhabdomyosarcoma (RMS) after 1 year of age.

210 ntreated patients with incompletely resected embryonal rhabdomyosarcoma (RMS), undifferentiated sarco

211 activity as single agents in both zebrafish embryonal rhabdomyosarcoma and a human cell line of rhab

212 The childhood cancer embryonal rhabdomyosarcoma can arise in tissue without s

213 chanisms that prevent MyoD activity in human embryonal rhabdomyosarcoma cells.

214 e a cell of origin for Sonic Hedgehog-driven embryonal rhabdomyosarcoma in an adipocyte-restricted co

215 tiation block in the childhood muscle cancer embryonal rhabdomyosarcoma is often thought to hold prom

216 se with non-metastatic incompletely resected embryonal rhabdomyosarcoma occurring at unfavourable sit

217 A diagnosis of embryonal rhabdomyosarcoma was made.

218 A KRAS(G12D)-induced zebrafish embryonal rhabdomyosarcoma was then used to assess the t

219 a secondary tumour (head and neck anaplastic embryonal rhabdomyosarcoma), all patients were alive at

220 nt of lineage (alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma), are particularly sensitive

221 in tumors, relapsed high-risk neuroblastoma, embryonal rhabdomyosarcoma, acute myeloid leukemia, and

222 partitioning of tumour-propagating cells in embryonal rhabdomyosarcoma, emergence of clonal dominanc

223 ic variegated aneuploidy, including two with embryonal rhabdomyosarcoma, we identified truncating and

224 Introduction of miR-1 and miR-133a into an embryonal rhabdomyosarcoma-derived cell line is cytostat

225 on-arrested and proliferative phenotypes for embryonal rhabdomyosarcoma.

226 potential therapeutic targets for high-risk embryonal rhabdomyosarcoma.

227 associated with intermediate- and high-risk embryonal rhabdomyosarcomas (ERMS).

228 atous testicular germ-cell tumors, in 2 of 5 embryonal rhabdomyosarcomas, and in 1 of 266 epithelial

229 RMS (age 21 years or younger) or metastatic embryonal RMS (age 2 to 10 years) were enrolled between

230 ntly observed in alveolar RMS (ARMS) than in embryonal RMS (ERMS) (81% v 32%, respectively; P < .001)

231 urvival (FFS) rate was 90% for patients with embryonal RMS (ERMS) stage 1, group I or IIa; stage 2, g

232 In embryonal RMS (eRMS), HO-1 expression was induced by Pax

233 arcoma, has two major histological subtypes: embryonal RMS (ERMS), which has a favorable prognosis, a

234 There are two main subgroups, embryonal RMS and alveolar RMS (ARMS).

235 und in 96%, 100% and 62% of metastatic GIST, embryonal RMS and LMS samples, respectively.

236 e environment for spontaneous development of embryonal RMS associated with mutation of p53 and mutati

237 as necessary for growth of alveolar RMS and embryonal RMS both in vitro and in vivo.

238 in RNA (shRNA) library in an alveolar and an embryonal RMS cell line.

239 MS cells express higher levels of c-MET than embryonal RMS cell lines and "home/seed" better into bon

240 ooperate to induce apoptosis in alveolar and embryonal RMS cells in a highly synergistic fashion (com

241 e embryonal RMS, stage 2/3, group III (33%); embryonal RMS, group IV, less than age 10 years (7%); al

242 MS), except those younger than 10 years with embryonal RMS, have an estimated long-term event-free su

243 Treatment strata were embryonal RMS, stage 2/3, group III (33%); embryonal RMS

244 For embryonal RMS, there was no statistically significant di

245 RLND alters prognosis for alveolar but not embryonal RMS.

246 a (n = 2), hamartoma (n = 1), and metastatic embryonal sarcoma (n = 1).

247 tofibrosarcoma protuberans, undifferentiated embryonal sarcoma of the liver, or unclassified malignan

248 e mesenchymal hamartoma and undifferentiated embryonal sarcoma, which have different origins but simi

249 actor critical for the pluripotency of human embryonal stem (ES) and induced pluipotency stem (IPS) c

250 tween pathways that regulate pluripotency in embryonal stem (ES) cells and oncogenesis.

251 MARY-X spheroids expressed embryonal stem cell markers including stellar, rex-1, ne

252 wn Oct4 and Stat3 systems required for early embryonal stem cell potency and self-renewal.

253 isms, being required for the self-renewal of embryonal stem cells in response to leukemia inhibitory

254 rowth as well as regenerative therapies with embryonal stem cells.

255 st SOX2, a gene critical for self-renewal in embryonal stem cells.

256 type AML) and miR-1 and miR-133 (involved in embryonal stem-cell differentiation), respectively.

257 strong risk of metastasis compared with the embryonal subtype (ERMS).

258 ines representative of both the alveolar and embryonal subtypes.

259 ion, i.e. the canonical pathway, in mouse F9 embryonal tetratocarcinoma cells expressing rat Frizzled

260 o oncogenic chromosome dynamics and that the embryonal theory for cancer cell growth/proliferation is

261 on embryonal characteristics, the so called embryonal theory of cancer.

262 While there is a long history of targeting embryonal tissues toward cancer vaccines, recent identif

263 viously, we observed expression of Oct-4, an embryonal transcriptional regulator, in osteosarcoma cel

264 ule network is partially disorganised in the embryonal tube cells and the microtubules disrupted in t

265 spensor cells on the other, separated by the embryonal tube cells.

266 ally invasive or metastatic tumors, in which embryonal tumor cells are EGFR-negative, while SCU cells

267 Conversely, at an older age, mice escaping embryonal tumor formation present with malignant gliomas

268 et consistent with a time-limited window for embryonal tumor initiation.

269 toma and neuroblastoma exemplify the current embryonal tumor model.

270 lopment and the medulloblastoma, a malignant embryonal tumor of the cerebellum, have proven especiall

271 oter hypermethylation in medulloblastoma, an embryonal tumor of the cerebellum.

272 Neuroblastoma (NB) is a malignant embryonal tumor of the sympathetic nervous system that i

273 Medulloblastoma is an embryonal tumor thought to arise from the granule cell p

274 Hepatoblastoma is a rare embryonal tumor with unknown etiology.

275 ulloblastoma/primitive neuroectodermal tumor/embryonal tumor, 17 had malignant astrocytoma, nine had

276 after diagnosis and treatment of a pediatric embryonal tumor.

277 normal development, supporting the model of embryonal tumorigenesis.

278 or of unknown cause, is not associated with embryonal tumors and cells from these individuals show m

279 Pediatric patients with CNS embryonal tumors are at high risk for treatment-related

280 Genomic analysis shows that embryonal tumors have more structural and copy number va

281 unger than 3 years with primary intracranial embryonal tumors is now in progress.

282 are highly aggressive, poorly differentiated embryonal tumors occurring predominantly in young childr

283 selective radioimmunoconjugates specific for embryonal tumors of childhood are currently being active

284 Embryonal tumors with multilayered rosettes (ETMRs) are

285 Embryonal tumors with multilayered rosettes (ETMRs) are

286 lip-derived mossy fiber neuronal lineage and embryonal tumors with multilayered rosettes fully recapi

287 Intraocular medulloepitheliomas and embryonal tumors with multilayered rosettes of the brain

288 RIP13 or BUB1B mutations have a high risk of embryonal tumors, and here we show that their cells disp

289 c tumors representing sarcomas, extracranial embryonal tumors, brain tumors, hematologic malignancies

290 ne abdominal wall defects, macroglossia, and embryonal tumors, is a model for understanding the relat

291 y have utility for this and other MYC-driven embryonal tumors.

292 en younger than 3 years with newly diagnosed embryonal tumors.

293 Medulloblastoma is the most common embryonal tumour in children.

294 Wilms tumour is an embryonal tumour of childhood that closely resembles the

295 Neuroblastoma, an embryonal tumour of the peripheral sympathetic nervous s

296 prises a biologically heterogeneous group of embryonal tumours of the cerebellum.

297 Choriocarcinomas are embryonal tumours with loss of imprinting and hypermethy

298 Embryonal tumours with multilayered rosettes (ETMRs) are

299 cle-like differentiation of RMS cells of the embryonal variant.

300 Growth of human embryonal WI38 fibroblasts is highly dependent on fibrob